Ensysce Biosciences, Inc. (ENSC): Nasdaq/NYSE listing notice — Ensysce Biosciences receives Nasdaq deficiency notice for bid price below $1.00, given 180 days to comply

Ensysce Biosciences, Inc.

Received Nasdaq deficiency letter on March 27, 2024 for bid price closing below $1.00 for 30 consecutive business days.
Has until September 23, 2024 to regain compliance by maintaining $1.00 bid price for at least 10 consecutive business days.
Also has prior stockholders' equity non-compliance; Nasdaq Panel granted continued listing until May 13, 2024.
Company will monitor closing bid price and evaluate options, but no assurance of regaining or maintaining compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Ensysce Biosciences, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

March 27, 2024, Ensysce Biosciences Inc. (the “Company”) received a notice (the “Deficiency Letter”) from the listing qualifications department staff of The Nasdaq Stock Market (“Nasdaq”) stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the bid price for the Company’s common stock had closed below $1.00 per share for the previous 30 consecutive business days. Nasdaq requires that Ensysce common stock have a minimum bid price of at least $1 per share (the “Minimum Bid Price”). In accordance with Nasdaq listing rule 5810(c)(3)(A), the Company has 180 cal

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-24-011871

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.